Volume 17, Number 8—August 2011
Research
Novel Arenavirus Infection in Humans, United States
Table 3
Antibody (immunoglobulin G) against WWAV and LCMV in paired serum samples from humans with acute central nervous system disease or undifferentiated febrile illnesses, United States*
Case-patient no. |
Age, y, at illness onset |
Days after illness onset | Antibody titer, WWAV | Antibody titer, LCMV | Apparent
homologous virus |
|||||
---|---|---|---|---|---|---|---|---|---|---|
S1 |
S2 |
S1 |
S2 |
S1 |
S2 |
|||||
1 | 32 | 14 | 44 | <320 | 640 | <320 | <320 | WWAV | ||
2 | 65 | 15 | 61 | <320 | 2,560 | <320 | <320 | WWAV | ||
3 | 38 | 14 | 33 | <320 | <320 | 5,120 | 5,120 | LCMV | ||
4 | 51 | 2 | 68 | <320 | <320 | 320 | 20,480 | LCMV | ||
5 | 59 | 24 | 38 | <320 | <320 | 320 | 5,120 | LCMV | ||
6 | 72 | 0 | 15 | <320 | <320 | <320 | 640 | LCMV | ||
7 | 12 | 25 | 33 | <320 | <320 | 320 | 320 | Indeterminate | ||
8 | 25 | 47 | 123 | <320 | <320 | 320 | 320 | Indeterminate |
*WWAV, Whitewater Arroyo virus; LCMV, lymphocytic choriomeningitis virus; S1, first sample; S2, second (last) sample in paired samples.